Intra-Cellular Therapies, Inc.

215 articles about Intra-Cellular Therapies, Inc.

• Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

  1/2/2024

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 8:15 a.m. PT in San Francisco, CA.

• Intra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx Conference

  11/15/2023

  Intra-Cellular Therapies, Inc. today announced that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023 at 3:25 p.m. ET in Miami, FL.

• Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

  11/2/2023

  Intra-Cellular Therapies, Inc. announced its financial results for the third quarter ended September 30, 2023 and provided a corporate update.

• Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences

  10/31/2023

  Intra-Cellular Therapies, Inc. today announced that it will participate in two upcoming investor conferences.

• Intra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and Webcast

  10/26/2023

  Intra-Cellular Therapies, Inc. today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, November 2, 2023, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2023.

• Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

  9/20/2023

  Intra-Cellular Therapies, Inc. today announced that it will present at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023 at 1:15 p.m. ET.

• Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features

  9/11/2023

  Intra-Cellular Therapies, Inc. today announced several CAPLYTA data presentations at the 2023 Psych Congress held September 6 - 10, 2023 in Nashville.

• Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

  9/5/2023

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023 at 12:55 p.m. ET.

• 

  The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch

  8/14/2023

  With a potential $509 billion up for grabs by 2028, companies including Biogen, Sage, Karuna Therapeutics and Cerevel Therapeutics are vying to bring their drugs across the regulatory finish line.

• Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference

  8/4/2023

  Intra-Cellular Therapies, Inc. today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 at 1:30 p.m. ET.

• Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

  8/3/2023

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the second quarter ended June 30, 2023 and provided a corporate update.

• Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast

  7/28/2023

  Intra-Cellular Therapies, Inc. today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, August 3, 2023, to provide a corporate update and discuss details of the Company's financial results for the quarter ended June 30, 2023.

• Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

  6/5/2023

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced that it will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023 at 2:00 p.m. PT.

• Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

  5/31/2023

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced several CAPLYTA data presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held in Miami, May 30 - June 2, 2023.

• Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/4/2023

  Intra-Cellular Therapies, Inc. today announced its financial results for the first quarter ended March 31, 2023 and provided a corporate update.

• Intra-Cellular Therapies to Present at Two Upcoming May 2023 Investor Conferences

  5/2/2023

  Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced that it will present at two upcoming investor conferences.

• Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast

  4/26/2023

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, May 4, 2023, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2023.

• Intra-Cellular Therapies to Present at the 22nd Annual Needham Virtual Healthcare Conference

  4/11/2023

  Intra-Cellular Therapies, Inc. announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 at 11:45 a.m. ET.

• 

  Positive Phase III Builds Case for Intra-Cellular's Depression Drug

  3/29/2023

  Intra-Cellular Therapies’ Caplyta met its primary endpoint in the Phase III Study 403 trial, easing the burden of depressive episodes in patients with major depressive disorder or bipolar depression.

• Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

  3/1/2023

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.